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24
Mitochondria are dynamic organelles forming a tubular network that is continuously 25 fusing and dividing to control their morphology and functions. Recent literature has shed new 26 light on a potential link between the dynamic behavior of mitochondria and muscle development.
27
In this study, we investigate the role of mitochondrial fission factor, dynamin-related protein 1 28 (Drp1), in myogenic differentiation. We found that differentiation of C2C12 myoblasts induced (16, 38, 50) . Upon activation, they recapitulate embryonic muscle development, which 53 involves proliferation, cell cycle withdrawal, and subsequent differentiation to fuse into 54 multinucleated syncytial myotubes (9, 41) . During this highly orchestrated multi-step process, 55 mitochondria undergo extensive remodeling in their morphology, activity, and content (2, 33, 43) 56 suggesting an essential role of mitochondria in successful myogenic progression. the mitochondrial outer and inner membranes is mediated by mitofusin 1 and 2 (Mfn1 and Mfn2) 63 and optic atrophy 1 (OPA1), respectively. Fission is mediated by dynamin related protein 1 64 (Drp1) and fission protein 1 (Fis1) (15). Growing evidence suggests that the balance between the 65 rates of fission and fusion contributes to mitochondrial quality control and response to stress, 66 influencing cell survival and death via maintaining mitochondrial homeostasis (58, 60).
67
Mitochondrial dynamics has also been implicated in the regulation of intracellular ROS 68 production (62). Recently, the physiological importance of the mitochondrial dynamics in 69 normal muscle development has begun to be elucidated (8). in the regulation of cell survival, apoptosis, and mitophagy (27, 35 penicillin/streptomycin at 37°C and 5% CO 2 . Primary myoblasts were isolated from hindlimb 102 muscles of two-week-old pups as we previously described (47). Myogenecity determined by 103 Pax-7 staining was over 90 % of total number of cells in each culture (Data not shown).
104
Myoblast differentiation was initiated when they reached 90 -95% confluency by incubating the 105 cells in differentiation media (DM) consisting of DMEM supplemented with 2% horse serum
106
(Invitrogen) and 1% penicillin/streptomycin. For some experiments, C2C12 myoblasts were 107 maintained in DM supplemented with small molecule mitochondrial division inhibitor (mdivi-1, 108 between 1 -20 μM in DMSO, DMSO final conc. = 0.2%) and insulin (1 μg/ml) for the indicated 109 period of time. IC 50 of mdivi-1 is ~10 μM. Control cells were treated with 0.2% DMSO in DM.
110
For some experiments, DM was supplemented with ROS scavengers Mito-TEMPO (25 μM)
111
(Enzo Life Sciences) and N-Acetyl-L-Cysteine (NAC) (500 μM) (Sigma-Aldrich) in the 112 presence or absence of mdivi-1 (10 μM). During differentiation, media was changed every 24 113 hours. Transfection. C2C12 cells were stably transfected with pcDNA3-Drp1-GFP or pcDNA3-117 Drp1(K38A) using FuGENE 6 (Promega) according to the manufacturer's instruction.
118
Selectively generated stable transfectants were maintained for more than three weeks in G418
119
(200 μg/ml) containing medium. G418 was added to all media used for the following 120 experiments. Subcellular fractionation. For Drp1 translocation assay and creatine kinase activity assay, 124 subcellular fractionation was performed using a protocol modified from Frezza et al. (2007) (19) .
125
Briefly, the cell pellet was resuspended in isolation buffer (320 mM Sucrose, 1 mM EGTA, 10 126 mM Tris-HCl, pH 7.4) and disrupted using a Dounce homogenizer. To remove precipitated 127 nuclei, membranes and non-disturbed large cell debris, the homogenized sample was initially 128 centrifuged at 1,000 g for 10 min at 4 °C. Then, the supernatant was centrifuged at 10,000 g for 129 15 min at 4°C. Subsequently, the subfractioned mitochondrial pellet and cytosolic fractions were 130 lysed in RIPA buffer and subjected to a Bradford assay for protein quantification. areas having a minimum number of three nuclei were considered to be differentiated myotubes. TIF1, HPRT1, and GAPDH were used as controls to ensure reliability of the assay. The primer 231 sequences used are described in Table 1 . by replacing GM with DM as described above. The majority of myoblasts were differentiated 249 and fused to form multinucleated syncytial myotubes indicated by myonuclei per field of ~ 60% 250 within three days in DM (Fig 1A) . During the three day differentiation period, protein expression 251 of Drp1 was significantly and gradually upregulated (to ~350% in 3 days) (Fig. 1B) complementary reduction in the amount of cytosolic Drp1 (Fig. 1D, left panel) . The significantly suppressed by mdivi-1 treatment in differentiating C2C12 cells (Fig. 3A and 3B ).
287
Also, the muscle fiber specific gene MHC I mRNA level was remarkably decreased in the 288 presence of mdivi-1 (Fig. 3A and 3B ). We also measured CK activity in the differentiating 289 myotubes. CK activity was significantly diminished in mdivi-1 treated differentiating myotubes 290 compared to the control (Fig. 3C) . Accordingly, immunostaining showed a dramatic decrease in 291 total myosin expression levels in mdivi-1 treated myotubes derived from both C2C12 cells and 292 primary myoblasts (Day 3) (Fig. 4A, top panel) . Analysis of the number of myonuclei per field (Fig. 4B ).
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Inhibition of Drp1-dependent mitochondrial division and apoptosis. To assess whether 302 inhibition of Drp1 increase cell death, we assessed the activated form of caspase-3, an 303 executioner caspase. A 3.5-fold increase in caspase-3 activation was observed shortly after 304 induction of myogenic differentiation ( Figure 5A ). Under the Drp1 inhibited condition, increased 305 caspase-3 activation was observed at 6 and 9 hours of differentiation (Fig. 5B) . Also, we 306 observed a dramatic increase in number of floating dead cells in mdivi-1 treated condition over 307 the entire experimental period in a dose-dependent manner as shown in the phase-contrast 308 micrographs (Fig. 5C) . Furthermore, mdivi-1 significantly increased the number of TUNEL-309 positive cells (up to 10-fold) in a dose-dependent manner (Fig. 5D) . 
313
We first measured mtDNA copy number as a surrogate marker for mitochondrial content in 314 differentiating myotubes which were cultured in mdivi-1 or DMSO supplemented DM for 3 days.
315
There was a significant increase in mtDNA copy number in 0 μM of mdivi-1 treated myotubes 316 compared to the subconfluent myoblasts. In addition, we observed a significant and dose- (Fig. 6D) . To confirm the observed difference in mitochondrial biogenesis, we 320 stained cells with MitoTracker Red (Fig. 6A ), a lipophilic cation dye which is sensitive to the (Fig. 6C) . 
360
On the other hand, the mitochondrial fission process has been recognized as an important initial 361 step to induce apoptosis through modulating mitochondrial outer membrane permeabilization 362 and cytochrome c release (3, 60) . Thus, we initially hypothesized that inhibition of Drp1 would 363 decrease apoptosis. Surprisingly, however, we observed that inhibition of Drp1-mediated We found that the imbalance between mitochondrial fission and fusion events hinders 375 successful mitochondrial remodeling during myogenic differentiation (Fig. 6) . During myogenic 
Mdivi-1 and myogenic differentiation
450
In this study, we used the Drp1 specific inhibitor mdivi-1 to examine whether the 451 functional impairment of Drp1 would directly modulate C2C12 myotube differentiation. The 452 mdivi-1 targets the allosteric site of Drp1 and suppresses its conformational change which is 453 necessary for Drp1 self-assembly and GTPase activity (4). It has been shown that mdivi-1 454 inhibits mitochondrial division to a similar extent as that of the dominant negative mutation,
455
Drp1 K38A (4, 18). Based on the previous study, we expected that the introduction of mdivi-1 456 could be used as a reliable tool to dissect the exact role of Drp1 throughout myogenic 457 differentiation as it has already proven to be a selective, rapid, and reversible inhibitor of Drp1 458 with reduced indirect effects as opposed to genetically modified models using mutant, knockout 459 cells, or RNAi techniques (34). Recently, mdivi-1 has emerged as a potential novel therapeutic 460 compound for heart failure, cardiac ischemia-reperfusion injury, pulmonary hypertension, and
461
Parkinson's disease (11, 21, 34, 37, 46) . While it is too early to be conclusive, the results from 
